School of Medicine
Showing 11-20 of 82 Results
-
Irogue I Igbinosa
Instructor, Obstetrics & Gynecology - Maternal Fetal Medicine
BioIrogue Igbinosa, MD, MS, is a Maternal-Fetal Medicine physician at Stanford University. She is currently an NIH Women's Reproductive Health Scholar (K12), and her research focus includes iron deficiency anemia in pregnancy, severe maternal morbidity and mortality, and health equity.
She graduated from the University of Houston and earned her medical degree at Baylor College of Medicine. She subsequently completed her residency in Obstetrics and Gynecology Residency at Louisiana State University School of Medicine Baton Rouge. After residency, she was an AAMC-CDC Public Health Policy Fellow able to serve in the CDC Emergency Operations Center and contribute to research for healthcare providers regarding the management of the Zika virus in pregnant persons. She completed her Maternal Fetal Medicine fellowship at Stanford in 2022.
Dr. Igbinosa is passionate about community-engaged approaches to bridge gaps in evidence-based care for birthing communities and collaborates with local and national policy committees to raise awareness for reproductive justice in maternal health. Her motto is to listen first and serve with compassion. -
Debra M. Ikeda, M.D.
Professor of Radiology (Breast Imaging), Emerita
Current Research and Scholarly InterestsMy research interests are mammography positioning, tomosynthesis (DBT) cancer detection and diagnosis, MRI, DWI, MRI-guided breast biopsy, breast cancer recurrence, tattoo/ fiducial/wire localization of axillary lymph nodes, breast cancer and FDG PET-CT imaging, artifical intelligence/deep learning, breast density, density notification legislation, COVID-19 effects on Breast Imaging Centers and personnel
-
Gentaro Ikeda
Instructor, Medicine - Cardiovascular Medicine
BioDr. Ikeda is a physician-scientist who develops innovative diagnostic and therapeutic modalities for patients with cardiovascular disease. Based on his clinical experience as a cardiologist, he has become aware of major clinical shortcomings, specifically in the current pharmaceutical therapies for myocardial infarction (MI) and chronic heart failure (HF). Some evidence-based drug therapies, including β-blockers, ivabradine, and renin-angiotensin-aldosterone antagonists are difficult to apply to critical patients due to adverse side effects. Drugs that have shown efficacy in basic animal experiments have failed to show significant benefits in clinical trials. To address these problems, he moved to academia to conduct translational research. During his graduate training in the Egashira Lab, he focused on drug delivery systems (DDS) that target mitochondria in animal models of MI. He obtained advanced skills in molecular biology, mitochondrial bioenergetics, and animal surgery. He realized the importance of translational research and the great potential of DDS to overcome many clinical problems. He developed nanoparticle-mediated DDS containing cyclosporine for the treatment of patients with MI. He published a first-author paper and received academic awards for his novel science. Since becoming a postdoctoral fellow in the Yang Lab, he has continued to build upon his previous training in translational research. He is currently developing an innovative therapy, namely, extracellular vesicles-mediated mitochondrial transfer for mitochondria-related diseases such as heart failure and mitochondrial disease.
